ARKAY Therapeutics, Logo

(609) 362-6818

Follow Us:LinkedIn


Dr. Ravi Kumar

Ravi Kumar, Ph.D.

Founder and CEO

Board Member

Dr. Ravi Kumar has served as the CEO and Scientific Director since 2014. He founded ARKAY with a mission to provide long-term glycemic control to Type 2 diabetes patients. Dr. Kumar has a unique combination of drug discovery and development expertise in metabolic, cardiovascular, and chronic inflammatory diseases.

Read More


Dr. Alan Lewis

Alan J. Lewis, Ph.D.

President and CEO, DiaVacs

Board Member

Dr. Alan J. Lewis is the President, CEO and board member of DiaVacs, a Type 1 diabetes company. DiaVacs is developing products to reverse the onset of autoimmune diseases by reinducing tolerance into the patient's immune system.

Read More


Stanley Schwartz

Stanley Schwartz, M.D.

FACP, FACE

Emeritus Associate Professor of Medicine, University of Pennsylvania. Currently in private practice

Advisor

Dr. Stanley Schwartz is a renowned endocrinologist, an expert and a key opinion leader in diabetes and cardiometabolic syndrome. Dr. Schwartz actively lectures nationally, as well as internationally, about diabetes and its treatment. In the past 4 years he has been a speaker in Turks/Caicos, Istanbul, Switzerland, Belgium, Tunisia, Spain, 11 cities in China, Philippines (AACE), Israel, Singapore and AACE 2011/2014, ADA 2014-(2015) and in October 2016 at Korean Diabetes Assoc.

Read More


Dr. Jialal

Ishwarlal (Kenny) Jialal, M.D., Ph.D.

Professor of Physiology, Metabolism & Pathology, California Northstate University College of Medicine
Editor-in-chief of Metabolic Syndrome & Related Disorders (2007-17)

Advisor

Dr. Jialal has published over 500 original papers and invited reviews in the areas of diabetes, atherosclerosis, lipid metabolism, nutrition and vascular biology. He has received numerous awards for his research, and has served on the editorial boards of numerous journals, including: American Journal of Clinical Nutrition, Journal of Molecular and Cellular Cardiology and Atherosclerosis. Currently, Dr. Jialal serves as section editor of the American Journal of Clinical Pathology for Clinical Chemistry.

Read More


Dr. Nancy Motola

Nancy C. Motola, PhD, RAC

Former Senior Vice President of Regulatory & Quality, Alexion Pharmaceuticals Inc.

Advisor

Nancy C. Motola, PhD, RAC, has over 30 years' experience in the Pharmaceutical Industry, encompassing both small molecules, biologics, and many therapeutic areas, in regulatory affairs and quality assurance, as well as chemical development/manufacturing. Through her consulting company, Pharma Regulatory Connection, she provides strategic Regulatory expertise for small/start-up, as well as large pharma companies.

Read More


Casey Case

Casey Case, Ph.D.

Senior Vice President, Research & Nonclinical Development, Asterias Biotherapeutics

Board Member

CASEY CASE, Ph.D. is senior vice president of research and nonclinical development at Asterias Biotherapeutics. Asterias is developing embryonic cell-based therapies for spinal cord injury and cancer.

Read More


Dr. Milton Grannatt

Milton H. Grannatt, Ph.D.

Retired Vice President, Global Business Development & Licensing Novartis Pharmaceuticals Corporation

Board Member

Dr. Grannatt retired September 2012 after 25 years in the global pharmaceuticals industry. He was Vice President of Global Business Development and Licensing at Novartis. Prior to Novartis, he held senior positions at Sterling Winthrop and Lex Service, an acquisitive, diversified UK-based company. Dr. Grannatt has an extensive deal sheet.

Read More


Paul Jeffrey

Paul Jeffrey, M.B.A.

Former Vice President, New Product Development & Commercialization, Pfizer

Board Member

Mr. Paul Jeffrey is an experienced business executive and advisor with over 35 years of pharmaceutical research, product development, marketing and business development experience. As vice president of early commercial development at Pfizer, he was responsible for commercial development of the entire portfolio of Rx pipeline products in Primary Care.

Read More


Dr. Martin Ogletree

Martin Ogletree, Ph.D.

Former Distinguished Research Fellow & Director of Thrombosis Research, Metabolic & Cardiovascular Drug Discovery, Bristol-Myers Squibb

Advisor

Dr. Ogletree led thrombosis research in Cardiovascular Drug Discovery at Merck Research Labs and at Bristol-Myers Squibb. At Merck he also led target identification and validation for the cardiovascular franchise.

Read More


Clifford M. Davidson

Clifford M. Davidson

Intellectual Property Attorney, Founding Partner, Davidson, Davidson & Kappel, LLC

Advisor

Clifford is a founding partner at Davidson, Davidson & Kappel, LLC, an Intellectual Property law firm with offices in New York. He counsels pharmaceutical clients in pharmaceutical patent-related matters, including patent prosecution, freedom to operate and infringement opinions, due diligence and tech transfer, and litigation. He has assisted pharmaceutical and biotech companies in creating significant and valuable patent portfolios covering their proprietary technologies.

Read More


Hemant N. Joshi

Hemant N. Joshi, Ph.D., MBA

Founder, TARA Innovations, LLC.

Advisor

Dr. Hemant Joshi is the founder of Tara Innovations LLC, a Pharmaceutical product development Contract Research Organization (CRO). He has over 27 years' experience as a Pharmaceutical Scientist. Tara is involved in product development, analysis and technology management.

Read More